Celularity Provides Update Regarding Nasdaq Listing Compliance

Rhea-AI Summary

Celularity (Nasdaq: CELU) reported that on August 21, 2026 it received a Nasdaq Listing Qualifications notice stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-Qs for quarters ended March 31 and June 30, 2026.

According to Celularity, Nasdaq has requested a compliance plan by September 4, 2026, and any exception would run no later than November 16, 2026. The notice has no immediate effect on the listing or trading of Celularity’s common stock, which continues on the Nasdaq Capital Market under the symbol CELU. The company is working to complete and file both quarterly reports as soon as practicable.

Positive

• Nasdaq notice has no immediate effect on CELU listing or trading
• Common stock continues trading on the Nasdaq Capital Market under symbol CELU
• Potential compliance exception period extends to November 16, 2026
• Company states it is working to file both outstanding Form 10-Qs

Negative

• Non-compliance with Nasdaq Listing Rule 5250(c)(1) due to late filings
• Delinquent on two Form 10-Qs: March 31 and June 30, 2026
• Nasdaq requires a compliance plan submission by September 4, 2026
• Risk of listing consequences if compliance not regained by November 16, 2026

News Explained

The two missing Form 10-Qs would provide unaudited interim financial statements and updates to risks and liquidity; Nasdaq’s notice currently leaves Celularity’s listing and trading unchanged.

Market Context

A prior Nasdaq notice produced a 5.94% 24-hour reaction, whereas two prior positive corporate update...

Analysis

A prior Nasdaq notice produced a 5.94% 24-hour reaction, whereas two prior positive corporate updates recorded -2.45% and -3.77%. That record adds divergence context; the key risk is unresolved reporting compliance.

Key Figures

Notification date: August 21, 2026 Delinquent filings: 2 Form 10-Q filings Nasdaq rule: 5250(c)(1) +3 more

6 metrics

Notification date August 21, 2026 Nasdaq compliance notification

Delinquent filings 2 Form 10-Q filings Periods ended March 31, 2026 and June 30, 2026

Nasdaq rule 5250(c)(1) Timely filing of required periodic financial reports

Compliance plan deadline September 4, 2026 Deadline requested by Nasdaq

Maximum exception 180 calendar days Maximum Nasdaq exception period

Exception end date November 16, 2026 Latest date stated for a possible exception

Historical Context

5 past events · Latest: Jun 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 04	Investigational availability	Positive	-2.5%	Cenplacel-L availability announced with Fountain Life under Florida regenerative medicine statutes
Jun 03	Shareholder letter	Positive	-2.5%	CEO letter highlighted strategic focus, liability reduction, and commercial efforts
Jun 03	Leadership appointment	Positive	-3.8%	Rick Gonzalez appointed Chief Commercial Officer to lead global commercialization
May 29	Nasdaq compliance notice	Negative	+5.9%	Nasdaq notice cited delinquent March 31 Form 10-Q filing
May 01	Annual filing	Positive	+2.8%	Form 10-K filing restored compliance with Nasdaq Listing Rule 5250(c)(1)

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

CELU's recent news reactions frequently diverged from the apparent announcement sentiment, including prior Nasdaq compliance news.

Key Terms

form 10-q, nasdaq listing rule 5250(c)(1)

2 terms

form 10-q regulatory

"Quarterly Report on Form 10-Q for the period ended June 30, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

nasdaq listing rule 5250(c)(1) regulatory

"not in compliance with Nasdaq Listing Rule 5250(c)(1)"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.

Nasdaq has requested that the Company submit its plan to regain compliance by September 4, 2026. Any exception granted by Nasdaq will be limited to a maximum of 180 calendar days from the prescribed due date of the initial delinquent filing, or until November 16, 2026.

The notification has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol “CELU.” The Company is working to complete and file both Quarterly Reports on Form 10-Q as soon as practicable

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing placental-derived cellular therapies. For more information, visit www.celularity.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company’s ability to complete its delayed filings and regain compliance with Nasdaq’s continued listing requirements. Actual results may differ materially due to risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

Contact

info@celularity.com

FAQ

What Nasdaq listing compliance issue did Celularity (NASDAQ: CELU) disclose on August 25, 2026?

Celularity disclosed it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because two Form 10-Q filings are delinquent. According to Celularity, the missing reports cover quarters ended March 31 and June 30, 2026, triggering a notification from Nasdaq’s Listing Qualifications Department.

Is Celularity (CELU) facing immediate delisting from Nasdaq after the August 21, 2026 notice?

Celularity is not facing immediate delisting; the Nasdaq notice has no instant effect on listing or trading. According to Celularity, its common stock continues to trade on the Nasdaq Capital Market under symbol CELU while it works to address the delinquent Form 10-Q filings.

What deadlines did Nasdaq give Celularity (CELU) to regain listing compliance in 2026?

Nasdaq asked Celularity to submit a plan to regain compliance by September 4, 2026. According to Celularity, any granted exception would extend for a maximum of 180 days from the original due date of the first late filing, or until November 16, 2026.

Why is Celularity (NASDAQ: CELU) non-compliant with Nasdaq Listing Rule 5250(c)(1)?

Celularity is non-compliant because it has not timely filed its required Form 10-Q reports for March 31 and June 30, 2026. According to Celularity, Nasdaq Listing Rule 5250(c)(1) requires listed companies to file all periodic financial reports on time with the SEC.

Does the Nasdaq compliance notice change how Celularity (CELU) stock trades today?

The notice does not currently change how Celularity stock trades; there is no immediate listing impact. According to Celularity, its common stock continues to trade on the Nasdaq Capital Market under symbol CELU while the company works to complete its delinquent quarterly filings.

How is Celularity responding to its delayed Form 10-Q filings and Nasdaq notice for CELU?

Celularity says it is working to complete and file both outstanding Form 10-Qs as soon as practicable. According to Celularity, it must also submit a formal plan to Nasdaq by September 4, 2026 to outline how it will regain listing rule compliance.